ZZ1003

ZZ1003 is a small molecule chemical drug that acts as a selective inhibitor of histone deacetylase 6 (HDAC6). It was initially developed by Shanghai Zhongze Pharmaceutical Technology Co., Ltd. The drug is in the discovery phase and has not yet entered clinical trials. Its primary therapeutic focus is on nervous system diseases and cardiovascular diseases, with active indications including Alzheimer’s disease, depressive disorder, schizophrenia, and stroke. As an HDAC6 inhibitor, ZZ1003 targets the HDAC6 enzyme to modulate epigenetic regulation and protein acetylation processes implicated in neurodegenerative and psychiatric disorders[1][2].